STOCK TITAN

Mediwound - MDWD STOCK NEWS

Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.

MediWound Ltd (Nasdaq: MDWD) is a biopharmaceutical innovator developing enzymatic therapeutics for non-surgical wound care. This page provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic developments.

Access consolidated information about NexoBrid adoption, EscharEx clinical trials, and pipeline progress. Stay informed about financial results, partnership announcements, and market expansion initiatives directly impacting MediWound's position in wound care innovation.

Key updates include FDA/EMA regulatory decisions, burn treatment protocols, chronic wound therapy breakthroughs, and peer-reviewed research findings. All content is verified through primary sources to ensure accuracy for investment and clinical decision-making.

Bookmark this page for streamlined access to MediWound's latest developments. Combine our updates with SEC filings and earnings call transcripts for comprehensive analysis of this enzymatic therapeutics leader.

Rhea-AI Summary
MediWound Ltd. (MDWD) announces commercial launch of NexoBrid in the U.S. and Japan, with a focus on meeting increased global demand. Cash of $46 million ensures operational cash runway through profitability. Third quarter 2023 revenues at $4.8 million, a decrease from $5.8 million in the same period last year. Gross profit at $0.9 million, operating loss at $3.0 million, and net loss at $2.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
-
Rhea-AI Summary
MediWound Ltd. (MDWD) appoints Dr. Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, effective December 1, 2023. Dr. Hess brings over two decades of expertise in drug development and commercial operations in healthcare, with a track record of leading international operations and commercial activities in the global biopharma industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
management
-
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) to release Q3 2023 financial results on November 21, 2023. The company will host a conference call and webcast to discuss the results and provide corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences earnings
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) announced a positive opinion from the European Medicines Agency recommending a label expansion for NexoBrid to include all age groups for removal of eschar in patients with deep partial- and full-thickness thermal burns. This expansion is based on the results of a global Phase 3 trial and additional pediatric data, confirming NexoBrid's safety and efficacy. The expansion is expected to redefine the standard of care for severe burns and significantly increase the company's addressable market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none
-
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) and PolyMedics Innovations (PMI) have announced a collaboration to promote NexoBrid® in Germany, Austria, Belgium, the Netherlands, and Luxemburg. NexoBrid, a non-surgical solution for eschar removal in burns, complements PMI's existing product line, allowing for a comprehensive solution for burn patients. The agreement aims to drive increased utilization of NexoBrid in the specified regions, leveraging PMI's customer access and commercial resources.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
Rhea-AI Summary
MediWound collaborates with 3M Health Care for a pivotal study on venous leg ulcers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
Rhea-AI Summary
MediWound addresses emergency demand for NexoBrid to treat burn casualties
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
-
Rhea-AI Summary
MediWound receives additional funding of $6.5 million from the U.S. Department of Defense to develop NexoBrid as a non-surgical burn treatment solution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
none
-
Rhea-AI Summary
MediWound announces U.S. commercial availability of NexoBrid for eschar removal in burn patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
Rhea-AI Summary
MediWound successfully participated in the 20th European Burns Association Congress, featuring NexoBrid in 20 scientific presentations. The event showcased NexoBrid's application in various burn care scenarios.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
none
Mediwound

Nasdaq:MDWD

MDWD Rankings

MDWD Stock Data

184.81M
7.99M
19.75%
47.68%
8.65%
Biotechnology
Healthcare
Link
Israel
Yavne